Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.

Takahara N, Isayama H, Nakai Y, Sasaki T, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Koike K.

Cancer Chemother Pharmacol. 2013 Nov;72(5):985-90. doi: 10.1007/s00280-013-2278-7. Epub 2013 Sep 1.

PMID:
23995699
2.

Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.

Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I.

Ann Oncol. 2015 Jan;26(1):141-8. doi: 10.1093/annonc/mdu472. Epub 2014 Oct 14.

PMID:
25316259
3.

[A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].

Zhou Y, Huang J, Yang L, Chi Y, Qu T, Lü X, Wang JW.

Zhonghua Zhong Liu Za Zhi. 2012 Nov;34(11):860-4. doi: 10.3760/cma.j.issn.0253-3766.2012.11.014. Chinese.

PMID:
23291138
4.

A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.

Oh SY, Kwon HC, Jeong SH, Joo YT, Lee YJ, Cho Sh, Kang MH, Go SI, Lee GW, Kim Hg, Kang JH.

Invest New Drugs. 2012 Feb;30(1):350-6. doi: 10.1007/s10637-010-9507-2. Epub 2010 Aug 13.

PMID:
20706861
5.

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.

Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):953-64. doi: 10.1007/s00280-013-2272-0. Epub 2013 Aug 28.

PMID:
23982118
6.

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.

Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E.

Cancer Chemother Pharmacol. 2009 Jan;63(2):313-9. doi: 10.1007/s00280-008-0741-7. Epub 2008 Apr 9.

PMID:
18398614
7.

Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.

Kasuga A, Okano N, Naruge D, Kitamura H, Takasu A, Nagashima F, Furuse J.

Cancer Chemother Pharmacol. 2015 Mar;75(3):457-64. doi: 10.1007/s00280-014-2665-8. Epub 2014 Dec 30.

PMID:
25547407
8.

Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.

Umemura A, Nitta H, Sasaki A, Takahara T, Hasegawa Y, Wakabayashi G.

Hepatogastroenterology. 2014 May;61(131):814-20.

PMID:
26176079
9.

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.

Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB.

Invest New Drugs. 2012 Aug;30(4):1501-10. doi: 10.1007/s10637-011-9683-8. Epub 2011 May 13.

PMID:
21567184
10.

Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.

Oh SY, Ju YT, Choi SK, Ha CY, Lee WS, Kim HG, Lee GW, Kwon HC, Kang JH.

Invest New Drugs. 2011 Oct;29(5):1050-6. doi: 10.1007/s10637-010-9409-3. Epub 2010 Mar 19.

PMID:
20238142
11.

A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.

Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH, Lee KH, Chung HC.

Eur J Cancer. 2012 Mar;48(4):518-26. doi: 10.1016/j.ejca.2011.12.017. Epub 2012 Jan 12.

PMID:
22243774
12.

Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.

Ohkawa S, Okusaka T, Isayama H, Fukutomi A, Yamaguchi K, Ikeda M, Funakoshi A, Nagase M, Hamamoto Y, Nakamori S, Tsuchiya Y, Baba H, Ishii H, Omuro Y, Sho M, Matsumoto S, Yamada N, Yanagimoto H, Unno M, Ichikawa Y, Takahashi S, Watanabe G, Wakabayashi G, Egawa N, Tsuda M, Hosotani R, Hamada C, Hyodo I.

Br J Cancer. 2015 Apr 28;112(9):1428-34. doi: 10.1038/bjc.2015.103. Epub 2015 Apr 16.

13.

[Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer].

Shi YX, Xu RH, Jiang WQ, Zhang L, Lin TY, Li YH, Xia ZJ, Luo HY, Han B, Wang F, He YJ, Guan ZZ.

Ai Zheng. 2007 Dec;26(12):1381-4. Chinese.

PMID:
18076807
14.

S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.

Kim MK, Lee KH, Jang BI, Kim TN, Eun JR, Bae SH, Ryoo HM, Lee SA, Hyun MS.

Jpn J Clin Oncol. 2009 Jan;39(1):49-53. doi: 10.1093/jjco/hyn126. Epub 2008 Dec 5.

PMID:
19060295
15.

Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).

Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, Hanada K, Kimura Y, Maetani I, Okabe Y, Tani M, Ikeda T, Hijioka S, Watanabe R, Ohoka S, Hirose Y, Suyama M, Egawa N, Sofuni A, Ikari T, Nakajima T.

Cancer Chemother Pharmacol. 2012 May;69(5):1197-204. doi: 10.1007/s00280-012-1822-1. Epub 2012 Jan 17.

PMID:
22249272
16.

A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer.

Kim SY, Hong YS, Kim BC, Park JW, Choi HS, Jeong SY, Kim DY, Hong CW, Sohn DK, Jung KH.

Invest New Drugs. 2009 Jun;27(3):269-74. doi: 10.1007/s10637-008-9177-5. Epub 2008 Sep 25.

PMID:
18815728
17.

Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.

Oh SY, Kim HJ, Kim TH, Lee GW, Kim HG, Jeong CY, Kwon HC, Kang JH.

Invest New Drugs. 2010 Jun;28(3):343-9. doi: 10.1007/s10637-009-9265-1. Epub 2009 May 15.

PMID:
19444385
18.

Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.

Lee SJ, Cho SH, Yoon JY, Hwang JE, Bae WK, Shim HJ, Chung IJ.

Cancer Chemother Pharmacol. 2009 Dec;65(1):159-66. doi: 10.1007/s00280-009-1019-4. Epub 2009 May 29.

PMID:
19479256
19.

Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.

Song H, Han B, Park CK, Kim JH, Jeon JY, Kim IG, Kim HJ, Jung JY, Kim JH, Kwon JH, Jang G, Kim HY, Kim HS, Choi DR, Zang DY.

Cancer Chemother Pharmacol. 2013 Oct;72(4):845-52. doi: 10.1007/s00280-013-2265-z. Epub 2013 Aug 27.

PMID:
23978987
20.

Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer.

Isayama H, Nakai Y, Yamamoto K, Sasaki T, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Arizumi T, Togawa O, Ito Y, Matsubara S, Yamamoto N, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M, Koike K.

Oncology. 2011;80(1-2):97-101. doi: 10.1159/000328767. Epub 2011 Jun 13.

PMID:
21677453

Supplemental Content

Support Center